Levetiracetam Combix

Levetiracetam, the active ingredient in Levetiracetam Combix, is an anticonvulsant presented as a tablet for oral use. It treats partial‑onset seizures, generalized tonic‑clonic seizures and myoclonic seizures in patients with epilepsy across the European market.\n\nGNH India supplies Levetiracetam Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug that modulates neuronal excitability in various seizure types.\n\nPartial‑onset seizures: reduces seizure frequency in patients with focal epilepsy.\nGeneralized tonic‑clonic seizures: helps prevent convulsive episodes in generalized epilepsy.\nMyoclonic seizures: decreases myoclonic jerks in patients with juvenile myoclonic epilepsy.

Levetiracetam is generally well tolerated, but adverse reactions can occur.\n\nCommon Side Effects:\n- Dizziness\n- Fatigue\n- Headache\n- Somnolence\n- Irritability\n- Nausea\n\nSerious or Rare Side Effects:\n- Severe allergic reactions (e.g., anaphylaxis)\n- Stevens‑Johnson syndrome or toxic epidermal necrolysis\n- Suicidal thoughts or behavior\n- Blood dyscrasias (e.g., neutropenia)\n- Severe skin rash\n- Multi‑organ involvement such as hepatic injury

Before initiating levetiracetam, consider patient‑specific factors and monitor for adverse events.\n\nRenal impairment: adjust dose based on creatinine clearance.\nHepatic impairment: monitor liver function tests.\nPregnancy: risk unknown; discuss potential benefits and risks with a healthcare professional.\nPsychiatric symptoms: observe for mood changes, depression, or aggression.\nConcomitant CNS depressants: use caution as additive sedation may occur.\nStore at room temperature: keep in the original container, protect from moisture and direct sunlight.

Levetiracetam may interact with other medicines, requiring attention to dosing and monitoring.\n\nMajor Interactions (Avoid):\n- Carbamazepine: induces metabolism, lowering levetiracetam levels.\n- Phenytoin: reduces levetiracetam exposure.\n- Rifampin: accelerates clearance, decreasing efficacy.\n\nModerate Interactions (Monitor Closely):\n- Valproic acid: may increase risk of adverse CNS effects.\n- Topiramate: additive sedation or cognitive effects may be observed.